Related Experiment Video

Updated: Jun 14, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East

Bassem I Yamout1, Maurice Dahdaleh, Mohammed Ali Al Jumah

  • 1Internal Medicine, American University of Beirut, Beirut, Lebanon. yamoutba@idm.net.lb

The International Journal of Neuroscience
|April 9, 2010
PubMed

Insights

Patient adherence to multiple sclerosis (MS) therapy is crucial for treatment efficacy. Local MS specialists in the Middle East discussed challenges and recommendations for improving patient adherence to disease-modifying drugs.

Area of Science:

  • Neurology
  • Pharmacology
  • Public Health

Background:

  • Therapy adherence is critical for managing chronic illnesses like multiple sclerosis (MS).
  • Specific aspects of MS and its treatments can lead to patient nonadherence and treatment discontinuation.
  • Compromised adherence negatively impacts the effectiveness of disease-modifying drugs (DMDs) in MS patients.

Purpose of the Study:

  • To address challenges related to patient adherence in multiple sclerosis (MS) within the Middle East.
  • To identify key factors contributing to nonadherence and treatment discontinuation in MS patients.
  • To develop expert recommendations for enhancing treatment adherence in the region.

Main Methods:

  • A consensus discussion among local multiple sclerosis (MS) specialists from the Middle East.
  • Debate on critical questions concerning the characteristics and causes of patient nonadherence.
  • Formulation of practical recommendations for improving adherence.

Main Results:

  • Identified specific features of MS and its treatment that pose adherence challenges.
  • Discussed the multifaceted causes of patient nonadherence to therapy.
  • Generated a set of expert-driven recommendations tailored for the Middle Eastern context.

Conclusions:

  • Improving adherence to disease-modifying drugs is essential for optimizing multiple sclerosis (MS) management.
  • Addressing patient-specific and treatment-related factors is key to enhancing adherence.
  • Regional expert consensus provides a foundation for targeted interventions to improve MS patient outcomes.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...